Open AccessDILTIAZEM HCL MICROCAPSULES USING ETHYL CELLULOSE ETHER DERIVATIVE POLYMER AS RELEASE RETARDING AGENT: IN-VITRO CHAPTER
Author(s) -
Kifayat Ullah Shah,
Gul Majid Khan,
Supriya Shah,
Asim Ur Rehman,
Abdul Wahab,
Naz Dilawar,
Kamran Khan
Publication year - 2015
Publication title -
international journal of research - granthaalayah
Language(s) - English
Resource type - Journals
eISSN - 2394-3629
pISSN - 2350-0530
DOI - 10.29121/granthaalayah.v3.i8.2015.2961
Subject(s) - ethyl cellulose , dissolution , dissolution testing , scanning electron microscope , chromatography , polymer , materials science , chemistry , fourier transform infrared spectroscopy , angle of repose , chemical engineering , nuclear chemistry , organic chemistry , composite material , engineering
This study presents sustained releasemicroencapsulation of Diltiazem HCL.
Its in-vitro dissolution study in phosphate buffer pH 7.4 as dissolution medium and in vivo behaviour in animal subjects. The microcapsules were prepared using polymers Ethocel 7P and Ethocel 7FP at two different drug to polymer (D: P) ratios i.e. 1:5 and 1:10 and the effect of concentration was observed on drug release behaviour. The prepared microcapsules were evaluated for different physical characteristics i.e. Bulk density, Tap density, Compressibility index, Hausner’s ratio and Angle of repose. Characterization of the developed microcapsules was carried out using Differential Scanning Calorimetery and Fourier Transform Infrared Spectroscopy while Scanning Electron Microscopy was performed to observe the morphology of the microcapsules. Model dependent and in dependent approaches were used to find out the drug transport mechanism and to compare the drug release profiles with standard formulation respectively.
All the formulations show anomalous, non-Fickian diffusion mechanism and the data was best fitted in Korsmeyer’sPeppas equation.
While carrying out in vivo studies, simple and rapid HPLC methods were developed which revealed optimum serum concentration (Cmax) levels for the developed microcapsules predicting least chances of side or adverse effects.